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Abstract
Objective – To identify prognostic variables for adult equids and foals with tetanus.
Design – Multicenter retrospective study (2000–2014).
Setting – Twenty Western, Northern, and Central European university teaching hospitals and private referral
centers.
Animals – One hundred fifty-five adult equids and 21 foals with tetanus.
Interventions – None.
Measurements andMain Results – Variables from history and clinical examination were statistically compared
between survivors and nonsurvivors (adults: 49 survivors, 85 nonsurvivors; foals: 7 survivors, 10 nonsurvivors).
Cases euthanized for financial reasons were excluded. Mortality rates in adults and foals were 68.4% and
66.7%, respectively. Variables associated with survival in adults included: standing, normal intestinal sounds
and defecation, voluntarily drinking, eating soft or normal food, lower heart and respiratory rates, high base
excess on admission, longer diagnosis time, treatment and hospitalization delay, and mild severity grade.
Variables associated with death included: anorexia, dysphagia, dyspnea, low blood potassium concentration
on admission, moderate and severe disease grading, development of dysphagia, dyspnea, recumbency and
seizuresduringhospitalization, treatmentwithglycerol guaiacolate, intravenousfluids, and intravenousglucose
solutions. Variables associated with survival in foals included standing on admission, voluntarily eating soft
food and drinking, older age, and longer hospitalization delay. Outcome was not different between different
tetanus antitoxin (TAT) dosages, although there was a trend of increasing survival rate with increasing TAT
dosages. Cases with appropriate vaccination prior to development of tetanus were rare, but had improved
outcome and shorter hospitalization.
Conclusions – Prognosis for equine tetanus is poor with similar outcome and prognostic factors in foals
and adults. The prognostic assessment of cases with tetanus provides clinicians with new evidence-based
information related to patient management. Several prognostic indicators relate to the ability to eat or drink,
and more severe clinical signs relate to poor outcome. Increasing intravenous dosages of TAT has no significant
effect on outcome, but the positive trend identified may support a recommendation for high intravenous TAT
dosages. Further evaluation is warranted.
(J Vet Emerg Crit Care 2017; (): 1–10) doi: 10.1111/vec.12669
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The prognosis for tetanus in horses is considered to
be poor, but survival rates vary considerably in previ-
ously published studies, ranging from 25%1 to 75%.2
In diseases with a poor prognosis, recognition of prog-
nostic indicators is valuable for appropriate case man-
agement and owner advice. Although the prognosis
for equine tetanus was assessed in previous studies,1–7
few have evaluated specific prognostic factors. The
previously published studies suffer from absent or
poorly defined case definitions, inclusion or exclusion
criteria,1–5,7 low case numbers and therefore poor sta-
tistical power,1,2,4–6 absence of multivariate statistical
analysis,1,2,4–7 inclusion of only a limited number of vari-
ables and no blood parameters,1,4,5,7 or have excluded
cases presented in a terminal state.5 In addition, most
reports only describe cases from before 20001–4,7 or do
not reflect the current approach in equine medicine in
Europe.5–7 Furthermore, although neonatal tetanus is
considered to be a separate entity in human medicine
with different prognostic factors compared with adult
tetanus,8 none of the previously published studies deter-
mined prognostic factors specifically for foals affected by
tetanus.
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Although intensive care techniques were practiced
in tetanus cases as early as the 1970s,9 intensive care
monitoring and therapeutic options are now more
widely available. Since human tetanus is considered
“a Third World disease that requires First World technol-
ogy for treating,” with mortality rates inversely cor-
related to the availability and adequacy of intensive
care management,10–12 recent developments in equine
veterinary care may potentially have had a signifi-
cant impact on survival rates. Moreover, administra-
tion of tetanus antitoxin (TAT)5,13 and different routes
of TAT administration are questioned1,6,13 and data on
the effects of TAT on the outcomes in equine patients
are very limited. In order to better manage affected
horses in an evidence-based manner, more information
about the variables that influence outcome in horses are
required.
The aims of this study were to identify variables that
had an impact on the outcome of adult horses and foals
thatwere recently treated in referral hospitals for tetanus,
and todeterminewhether the outcomeof those caseswas




and the European College of Equine Internal Medicine,
potential scientific collaborators were identified. The fol-
lowing criteria for collaborators were used: (1) Located
in Western, Northern, or Central Europe, (2) working
in an academic equine referral center or a large, private
referral center with a good reputation and interest in sci-
entific research, (3) working in a referral clinic where at
least one equine internal medicine specialist (Diplomate
ECEIM or ACVIM) is employed. At least one academic
clinic was searched and contacted for every country. All
collaborators who had diagnosed tetanus cases since the
year 2000 and who agreed to collaborate in the study,
received a case definition and a detailed, standardized
data spreadsheet for specific variables to be retrospec-
tively retrieved from the medical records. Subsequently,
all data were gathered and checked by the first author
(G. vanGalen), and analyzed by the first and last authors
(G. van Galen, C. Saegerman).
Case definition
The following case inclusion criteria were used for this
study: (1) cases with the clinical diagnosis of tetanus, (2)
admitted to the referral hospital of the collaborator, and
(3) admitted in the years 2000 to 2014. Since no definitive
diagnostic tests are available for tetanus, the diagnosis
of tetanus was based on the presence of the most typical
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Figure 1: (A and B) Groups of the tetanus cases for statistical comparisons. NS, nonsurvivor.
and consistent clinical signs reported in the published lit-
erature (eg, stiffness, trismus, or protrusion of the third
eyelid), and the absence of clinical signs, laboratory re-
sults and, where applicable, postmortem findings that
indicated any other disease that could explain the clinical
presentation.13 Cases with the following findings were
excluded from the study: (1) serumbiochemical evidence
of significant rhabdomyolysis (creatine kinase activity
of > 10,000 U/L, with or without myoglobinuria), (2)
hypocalcemia (ionized calcium< 1 mmol/L [2 mEq/L],
total calcium < 2 mmol/L [4 mEq/L]), (3) signs and
laboratory results suggestive of hepatic encephalopa-
thy or significant liver damage (gamma-glutamyl trans-
ferase activity> 150 U/L), and (4) signs or result of con-
comitant examinations suggestive of other neurological
conditions.
Retrieved data from reported cases and definitions
Detailed information about the cases was retrieved ret-
rospectively from themedical files with owner informed
consent. For a minority of the cases no consent could
be obtained because of absence of standard consent con-
tracts on admission and unsuccessful attempts to reach
the owner.Demographic- andmanagement-relateddata,
details of the clinical history, clinical examination on
admission, complications and clinical signs that devel-
oped during hospitalization, treatments and final out-
come were detailed in Part 1 of this study.15
Groups
Based on resemblance of the clinical parameters in foals
older than 6months and adults, and the fact that all foals
should theoretically have received a first vaccination at
this age, cases were divided into horses >6 months old
(adults) and <6 months old (foals). Figure 1 illustrates
a schematic explanation of the division of the tetanus
cases in groups based on outcome and age. Group 1 was
surviving adult horses, Group 2 surviving foals, Group 3
nonsurviving adult horses, Group 4 nonsurviving foals,
Group 5 surviving horses fromGhent University (adults
and foals), andGroup 6 nonsurviving horses fromGhent
University (adults and foals). Cases thatwere euthanized
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due to financial reasons were excluded from all nonsur-
vivor groups (Groups 3, 4, and 6).
Statistical Methods
Comparisons of surviving and nonsurviving groups
For the prognostic assessment of adult tetanus, Group 1
was compared to Group 3, and for a prognostic assess-
ment of foals with tetanus, Group 2 was compared to
Group 4. Additionally, to rule out institute-related bias,
a prognostic assessment of cases from Ghent University
was performed comparing Group 5 to Group 6. For all
statistical comparisons, horses that were euthanized due
to financial reasons and variables with a low response
rate (<30%) and low incidence were excluded. Statisti-
cal analyseswere performedusing commercial statistical
software.a P < 0.05 was considered significant.
Univariate analysis
To compare the surviving cases versus nonsurviving
cases, dichotomous and categorical variables were as-
sessed by odds ratio (OR), and quantitative variables
were assessed by a two-sample Wilcoxon rank-sum test.
When complete separation (zero cells) occurred, the Firth
logit method allowed interference of ORs and confi-
dence intervals. Severity gradeswere compared between
groups with a Fisher’s exact test.
Multivariate analysis
All variableswith aP-value< 0.05 in the univariate anal-
ysis were entered in a multivariate logistic regression
model. Two multivariate regressions were performed:
one where only the variables from the history and the
clinical examination on admission were taken into ac-
count, and one where only the variables after admission
were taken into account (complementary examinations,
complications, and treatments). To assess collinearity, a
backward elimination of variables was performed. Vari-
ables that induced amodification ofORof>20%were re-
tained in final analysis where the interaction was tested.
All pairwise interactions between the variables in the
final model were examined for significance (if biologi-
cally relevant). Goodness of fit was assessed using the
Hosmer–Lemeshow goodness-of-fit test.
Effect of TAT on outcome
The outcome of adult horses (Groups 1 and 3) treated
with intravenous TAT was compared with a Fisher’s ex-
act test among different categories of total dosage re-
ceived (<25,000 IU, 25,000–50,000 IU, 50,000–100,000 IU,
100,000–150,000 IU, 150,000–200,000 IU, >200,000 IU).
Results
In total, 185 cases were reported of which 176 cases ful-
filled the inclusion criteria for this study. Of those 176
cases, 120were nonsurvivors and 56were survivors, giv-
ing a survival rate of 31.8% and mortality rate of 68.2%.
Survival rate for the adult cases was 31.6% (49/155) and
for the foals 33.3% (7/21). Of the nonsurviving cases,
21 died, 22 were euthanized due to financial reasons,
and the remainder was euthanized for ethical/humane
reasons. Of the survivors, 93.8% were reported to have
fully recovered, but 2 horses suffered from sequelae:
1 horse was affected by an unspecified lameness and
another by ataxia. Three of the 4 correctly vaccinated
horses survived and had mild (2) and moderate (1) dis-
ease severity and shorter hospitalization periods (10, 12,
and 13 days) than other survivors (average 20.5 days).
The one that did not survive was euthanized for eth-
ical reasons, not for financial reasons. Correct vacci-
nation was doubtful since it was recently purchased
and the seller assured the new owners that the horse
was correctly vaccinated. For a full detailed descrip-
tion of the cases the readers are referred to Part 1 of
the study.15
Statistical analysis
Comparisons of surviving and nonsurviving groups
Forty-nine equids were allocated to Group 1, 7 to Group
2, 85 to Group 3, 10 to Group 4, 46 to Group 5 and 21 to
Group 6 (Figure 1). Variables associated with survival in
adult cases were as follows: standing, normal intestinal
sounds and defecation, voluntarily drinking, eating soft
and/or eating normal food on admission, and mild dis-
ease grading. Adult survivors had a significantly lower
heart rate, lower respiratory rates, higher blood potas-
sium concentration, higher base excess on admission,
and longer diagnosis time, treatment delay and hos-
pitalization delay compared to nonsurvivors. Variables
associated with nonsurvival in adults were: anorexia,
dysphagia, dyspnea on admission, moderate and severe
disease grading, development of dysphagia, dyspnea,
recumbency and seizures during hospitalization, treat-
ment with glycerol guaiacolate, intravenous fluids, and
intravenous glucose solutions (Tables 1 and 3). Although
no statistical significancewas identified, a trendwas seen
(P = 0.053) with survivors of the adult group having re-
ceived a higher total intravenous dosage of TAT than
nonsurvivors (survivors mean = 106 IU, range 186 ±
96,176, n = 42; nonsurvivors mean = 77 IU, range 164 ±
49,261 IU, n = 67; P = 0.053).
Variables associatedwith survival in foals were stand-
ing, voluntarily eating soft food, and drinking on ad-
mission. Survivors had a significantly older age and
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Table 1: Variables that are statistically different between adult surviving and nonsurviving tetanus cases (Group 1 vs Group 3)
Descriptive data Statistical comparison S versus NS
S (n = 49) NS (n = 85) UVA MVA
Categorical variables n N % n N % P-value OR CI 95 P-value
On admission
Standing 47 49 95.9 71 85 83.5 0.049 4.63 1.01–21.33
Anorexia 13 43 30.2 49 72 68.1 <0.001 0.20 0.09–0.46 0.026∗
Dysphagia 21 46 45.7 52 76 68.4 0.014 0.39 0.18–0.83
Dyspnea 11 45 24.4 38 68 55.9 0.001 0.26 0.11–0.59
Normal intestinal sounds 23 37 62.3 10 41 24.4 0.001 5.09 1.92–13.49
Defecation 27 35 77.1 8 36 22.2 <0.001 11.81 3.87–35.97 0.002∗
Grade of severityx
Moderate 20 49 40.8 37 85 43.5 0.005 0.30 0.13–0.69
Severe 6 49 12.2 37 85 43.5 <0.001 0.07 0.02–0.22
Complications/clinical signs developing during hospitalization
Dysphagia 23 48 47.9 65 73 89.0 <0.001 0.11 0.04–0.29
Dyspnea 7 48 14.6 57 76 75.0 <0.001 0.06 0.02–0.15
Recumbency 8 48 16.7 62 78 79.5 <0.001 0.05 0.02–0.13 <0.001
Seizures 1 48 2.1 24 78 30.8 0.003 0.05 0.006–0.37
Treatment
Glyceryl guaiacolate 3 49 6.1 20 80 25.0 0.012 0.20 0.05–0.70
IV fluids 36 49 73.5 77 80 96.3 0.001 0.11 0.03–0.40
Free drinking 44 49 89.8 29 77 37.7 <0.001 14.56 5.18–40.94 <0.001
Voluntary eating normal food 22 49 44.9 13 76 17.1 0.001 3.95 1.74–8.27
Voluntary eating soft food 32 45 71.1 15 75 20.0 <0.001 9.85 4.18–23.21
IV glucose 18 49 36.7 47 78 60.3 0.011 0.38 0.18–0.80
Numerical variables Mean SD N Mean SD N P-value UVA P-value MVA
Diagnosing time (days) 2.55 4.09 44 0.55 0.77 84 0.002
Treatment delay (days) 2.60 4.12 43 0.53 0.77 80 0.001∗
Hospitalization delay (days) 2.92 4.46 44 0.67 0.82 83 0.001
Heart rate (bpm) 55.51 11.81 47 68.07 19.78 76 0.0008
Respiratory rate (rpm) 35.30 20.75 40 46.99 26.08 67 0.02
Potassium (mmol/L or mEq/L) 3.77 0.38 23 3.37 0.33 34 0.0005
pH 7.40 0.04 18 7.36 0.07 33 0.04∗∗
Base excess (mmol/L) 2.67 3.18 24 0.03 5.63 50 0.047∗∗
∗Significantly different between groups in the multivariate analysis for variables on history and clinical examination on admission.
∗∗Significantly different between groups in the multivariate analysis for variables on complementary examinations, complications during hospitalization
and treatment.
xThe severity grades were defined as specified in van Galen et al. Part 1.15
S, surviving cases; NS, nonsurviving cases; SD, standard variation; OR, odds ratio to survive; CI 95, 95% confidence interval; N, number of horses with
a response for this specific parameter; n, number of horses with a positive response; UVA, univariate analysis; MVA, multivariate analysis. Group 1,
surviving adult horses (>6 months of age); Group 3, nonsurviving adult horses (>6 months of age). For Group 3, all cases that were euthanized due to
financial reasons were excluded.
longer hospitalization delay compared to nonsurvivors
(Tables 2 and 3).
Variables associated with good outcome in the Ghent
University cases were normal defecation, voluntary eat-
ing of soft food and freedrinking on admission. Those as-
sociatedwithnonsurvival included severedisease grade,
development of dysphagia, dyspnea and recumbency
during hospitalization, treatment with acepromazine
and glycerol guaiacolate administration. Survivors had a
significantly longer diagnosis time, treatment delay and
hospitalization delay, lower heart rate, higher base ex-
cess, and higher pH compared to nonsurvivors (Table 4).
For adult cases, anorexia, defecation, recumbency, and
free drinking were retained as prognostic indicators
(Table 1). For foals, only voluntarily eating soft food was
retained (Table 2). For the Ghent University cases, nor-
mal defecation, recumbency, and voluntary eating of soft
food were retained (Table 4).
Effect of TAT dosage on outcome
Outcome between the different total received TAT
dosages was not significantly different (P = 0.33),
C© Veterinary Emergency and Critical Care Society 2017, doi: 10.1111/vec.12669 5
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Table 2: Variables that are statistically different between surviving and nonsurviving tetanus foals (Group 2 vs Group 4)
Descriptive data Statistical comparison S versus NS
S (n = 7) NS (n = 10) UVA MVA
Categorical variables n N % n N % P-value OR CI 95 P-value
On admission
Standing 6 7 85.7 2 10 20.0 0.018 24 1.74–330.80
Treatment
Free drinking 6 7 85.7 2 8 25.0 0.033 18.0 1.27–255.74
Voluntary eating soft food 5 7 71.4 0 8 0.0 0.028 37.4 1.49–936.27 0.027@
Numerical variables Mean SD N Mean SD N P-value UVA P-value MVA
Age (years) 0.32 0.21 7 0.08 0.06 9 0.01
Hospitalization delay (days) 2.79 2.67 7 0.26 0.62 10 0.03
∗Significantly different between groups in the multivariate analysis for variables on history and clinical examination on admission.
@Significantly different between groups in the multivariate analysis for variables on complementary examinations, complications during hospitalization
and treatment.S, surviving cases; NS, nonsurviving cases; SD, standard variation; OR, odds ratio to survive; CI 95, 95% confidence interval; N, number
of horses with a response for this specific parameter; n, number of horses with a positive response; UVA, univariate analysis; MVA, multivariate analysis.
Group 2, surviving foals (<6 months of age); Group 4, nonsurviving foals (<6 months of age). For Group 4, all cases that were euthanized due to financial
reasons were excluded.
Figure 2: The outcome of adult horses that received intravenous tetanus antitoxin (TAT) according to the total administered dosage.
Group 1, surviving adult horses (>6 months of age); Group 3, nonsurviving adult horses (>6 months of age). For Group 3, all cases
that were euthanized due to financial reasons were excluded. The outcome was statistically not different between the different dosage
groups (P = 0.33).
although a trend of increasing survival rate with increas-
ing total dosages was observed, as shown in Figure 2.
Discussion
This study reports a prognostic assessment in a large
population of equids with tetanus, providing more
recent information on more variables compared to what
is available in the literature. Several prognostic indica-
tors for outcomewere identified that can assist clinicians
in making evidence-based decisions about initiating or
continuing treatment. It should be noted that this is a risk
analysis and by nomeans provides clear-cut answers for
all clinical cases. Although the presence of a specific poor
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Table 3: Comparison of severity grades among survivors and
nonsurvivors of tetanus in adult cases (Group 1 and 3) and foals
(Group 2 and 4) with a Fisher’s exact test
Adult horses
S (n = 49) NS (n = 85)
n N % n N % P-value
Mild 23 49 46.9 9 85 10.6 <0.001∗
Moderate 20 49 40.8 37 85 43.5 0.86
Severe 6 49 12.2 37 85 43.5 <0.001∗
Very severe 0 49 0.0 2 85 2.4 0.53
Foals
S (n = 7) NS (n = 10)
n N % n N % P-value
Mild 3 7 42.9 3 10 30.0 0.64
Moderate 3 7 42.9 0 10 0.0 0.051
Severe 1 7 14.3 5 10 50.0 0.30
Very severe 0 7 0.0 2 10 20.0 0.49
∗Significantly different between groups. The severity grades were defined
as specified in van Galen et al. Part 1.15
N, number of horses with a response for this specific parameter; n, number
of horses with a positive response. Group 1, surviving adult horses (>6
months of age); Group 3, nonsurviving adult horses (>6 months of age).
For Group 3, all cases that were euthanized due to financial reasons
were excluded. Group 2, surviving foals (<6 months of age); Group 4,
nonsurviving foals (<6 months of age). For Group 4, all cases that were
euthanized due to financial reasons were excluded.
prognostic clinical parameter carries an increased analyt-
ical risk for nonsurvival, outcome is not necessarily poor;
chance of survival is just expected to be lower thanwhen
the specific variable is absent. Therefore, the authors rec-
ommend to base irrevocable decisions of euthanasia on
the presence of multiple poor prognostic indicators, or
when those indicators do not improve following treat-
ment. In addition, the statistically significant differences
between survivors and nonsurvivors identified with the
univariate analysis do not take into account possible in-
teractions between the different variables tested. There-
fore, theymight not have a direct effect on outcome.With
the multivariate analysis, interactions between variables
are taken into account making them more reliable as
prognostic factors. In order to optimize use of prognos-
tic variables at different time points in casemanagement,
2 different multivariate analyses were performed. One
took into account the variables from history and the clin-
ical examination on admission, reflecting the first vet-
erinary visit and allowing prognostic assessment in an
early phase. A second multivariate analysis was under-
takenwith the variables fromconcomitant examinations,
complications, and treatments, allowing prognostic as-
sessment later on.
The majority of the prognostic indicators identified
in the current study are related to the ability to eat or
drink, and the subsequent required treatment. Normal
intestinal sounds and defecation, and voluntarily drink-
ing and eating soft or eating normal food were associ-
atedwith good outcome.Anorexia, dysphagia on admis-
sion, development of dysphagia during hospitalization,
necessity for treatment with intravenous fluids and in-
travenous glucose solutions, and low blood potassium
concentrationswere associatedwith poor outcome.Only
few of those variables were retained in the multivariate
analysis for each age group, probably because of strong
correlation between these variables. Multiple complica-
tions related to the gastrointestinal tract were reported
in Part 1 of the study (eg, hyperlipemia, gastrointestinal
impaction, weight loss, diarrhea, gastrointestinal disten-
sion, aspiration pneumonia, and cecal impaction with
subsequent rupture).15 These findings highlight how im-
portant a normal functioning gastrointestinal tract is for
the outcome of horses suffering from tetanus. Clinicians
should support this with close monitoring of the gas-
trointestinal tract, preventive or early treatment when
complications arise and focus on nutritional support.
The remaining prognostic factors were predominantly
related to severity of neuromuscular dysfunction and
respiratory compromise.
In addition to identifying prognostic factors in adult
horses with tetanus, the present study also identified
prognostic factors for foals with tetanus. The only report
of tetanus in the existing literature suggests extremely
poor outcomes for foals, with 6 out of 6 reported foals
dying.2 In human and canine neonates with tetanus,
the outcome is also worse than in adult cases.8,16–18 The
outcome for foals in the current study is comparable
to neonatal human cases (73.2% case fatality).8 With a
mortality rate of 68.4% and 66.7% for adult horses and
foals, respectively, therewas no significant difference be-
tween the outcomes of foals and adults in this study.
Onlywithin the foal group itself, younger agewas found
to be a poor prognostic indicator with all nonsurviving
foals being under the age of 2 months. This corresponds
with young age at onset of disease (<5–7 days) being a
poor prognostic indicator in human neonates affected by
tetanus.8,16
The overall survival rate in the present study was
similar to that recorded in several older equine studies
fromvarious countries and continents (41% inMorocco,5
23.7% inBrazil,7 25% inUnited States,1 32% inBelgium4).
Survival rates have clearly not improved compared to
studies from the 1970s that report equine survival rates
of 50%3 and 77.5%.2 Artificial ventilation following
central muscle relaxation is the critical care technique
that improved outcome over time in human beings, but
is currently not used in adult horses and could largely
explain this discrepancy.11,12 Although this is a well-
established technique for foals,19 artificial ventilation
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Table 4: Demographic, management-related, and clinical variables that are statistically different between surviving and nonsurviving
tetanus cases from Ghent university (Group 5 vs Group 6)
Descriptive data Statistical comparison S versus NS
S (n = 21) NS (n = 46) UVA MVA
Categorical variables n N % n N % P-value OR CI 95 P-value
On admission
Normal defecation 6 8 75 0 9 0 0.02 49.40 2.02–1207 0.02∗
Complications/clinical signs developing during hospitalization
Dysphagia 14 21 66.7 41 44 93.2 0.01 0.15 0.03–0.64
Dyspnea 4 21 19.0 29 44 65.9 0.001 0.12 0.03–0.43
Recumbency 2 21 9.5 31 44 70.5 <0.001 0.04 0.009–0.22 0.001@
Grade of severityx
Severe 0 21 0 21 46 45.7 0.006 0.016 0.0009–0.30
Treatment
Acepromazine 14 21 66.7 39 44 88.6 0.04 0.26 0.07–0.94
Glyceryl guaiacolate 14 21 66.7 39 44 88.6 0.02 0.20 0.050–0.78
Free drinking 16 21 76.2 6 44 13.6 <0.001 20.27 5.40–76.08
Voluntary eating soft food 13 21 61.9 2 44 4.5 <0.001 34.13 6.43–181.22 0.003@
Numerical variables Mean SD N mean SD N P-value UVA P-value MVA
Diagnosing time (days) 2.0 2.54 21 0.40 0.62 46 0.03
Treatment delay (days) 2.02 2.52 21 0.41 0.61 45 0.02
Hospitalization delay (days) 2.48 2.61 21 0.58 0.73 46 0.003
Heart rate (bpm) 56.80 12.30 20 70.84 22.52 44 0.02
pH 7.40 0.03 12 7.35 0.07 22 0.04
Base excess (mmol/L) 3.22 3.06 20 −0.09 5.68 39 0.009
∗Significantly different between groups in the multivariate analysis for variables on history and clinical examination on admission.
@Significantly different between groups in the multivariate analysis for variables on complementary examinations, complications during hospitalization
and treatment.
xThe severity grades were defined as specified in van Galen et al. Part 1.15
S, surviving cases; NS, nonsurviving cases; SD, standard variation; OR, odds ratio to survive; CI 95, 95% confidence interval; N, number of horses with
a response for this specific parameter; n, number of horses with a positive response; MVA, multivariate analysis. Group 5, surviving horses from Ghent
University; Group 6, nonsurviving horses from Ghent University. For Group 6, all cases that were euthanized due to financial reasons were excluded.
was not performed on any of the cases of the current
study. Total parenteral nutrition is frequently and easily
used in people. In the current study, partial parenteral
nutrition was used frequently in the form of intravenous
glucose solutions, but total parenteral nutrition was
only provided in very few cases (1.4%; see Part 1).15 Re-
gardless of treatment options, outcome is probably also
dictated by the amount of toxin, and the horse is known
as one of the most sensitive species to tetanus toxins.13,20
The current study shows that fewer prognostic factors
could be identified for foals than adults, probably due
to the smaller population size. Those factors that were
identified for foals, however, were similar to those of
adult cases, except for the variable age. Conversely,
human neonatal tetanus and adult tetanus have different
prognostic factors15,21,22 than those identified in horses
in the current study. Tachycardiawas the only variable in
the current study that was identified as a poor prognos-
tic indicator in adult equids similar to adult humans.20,21
Delay in admission of affected equids was found to be
a positive prognostic predictor, but is a poor prognostic
indicator in people.16 The association of a longer diag-
nosis, treatment, and hospitalization delaywith survival
in horses can be explained by the less severe and less ob-
vious clinical signs in survivors, and therefore delayed
recognition of the disease. Treatments associated with
poor prognosis in this study (ie, acepromazine, glycerol
guaiacolate, intravenous fluids, and intravenous glucose
solutions) also do not necessarily have a negative impact
on the patient, but patients with more severe disease
require additional and different therapeutic support.
Therefore, early diagnosis, treatment and hospitaliza-
tion are still recommended. Prognostic factors identified
in the Ghent University cases were largely similar to the
rest of the adult population, suggesting that there was
no apparent institution-related bias in this study.
Since the number of appropriately vaccinated horses
is very low in this study, it seems reasonable to suggest
that vaccination provides adequate protection against
tetanus, however it does not guarantee full protection.
In affected cases, appropriate vaccination prior to devel-
opment of tetanus seems to lead to less severe clinical
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signs, shorter disease period, and good outcome. There
is little evidence available on the effect of therapeutic
administration of TAT and its dosage in horses. There
is currently no consensus with regards to TAT adminis-
tration, with some authors suggesting a positive effect
on the outcome3 while others suggest that there is no
effect.5,7 TAT will not cross the blood-brain barrier and
cannot capture and inactivate bound tetanus toxin, but
it neutralizes circulating residual toxin. However, by the
time horses show clinical signs, circulating toxin might
not be detectable.13 Although TAT is considered part of
the standard treatment in horses,13 affected individuals
are reported to be able to survive tetanus without TAT
administration.3,5 The current study does not show sta-
tistical differences in therapeutic TAT use, its route of
administration, the timing of the first TAT or the total in-
travenous administered dosage between survivors and
nonsurvivors. A trend, with the P-value approaching
significance (P = 0.53), was seen with survivors having
received higher total dosages of TAT than nonsurvivors.
The survival rates were not statistically different for
horses treated with different total intravenous dosages,
though also a trend appeared in this comparison as well.
As efficacy cannot be determined via retrospective stud-
ies, it is clear that further research is warranted to deter-
mine the utility and optimal dosages of TAT in horses
with tetanus. Nevertheless, our results may support a
recommendation for high intravenous TAT dosages (to-
tal dosage>100,000 IU).With regards to intrathecal TAT,
too few cases (16) were treated to be able to see a differ-
ence between groups for this administration route in the
current study.
The most common antimicrobial used in the current
study was penicillin. Penicillin has been suggested to
have low efficacy for treatment of tetanus patients be-
cause of poor penetration into devitalized anaerobic
tissue, and deactivation by beta-lactamases produced
by coinfecting bacteria. Moreover, it has anti-gamma-
aminobutyric acid and therefore proconvulsant activity.
One report of human tetanus patients showed a posi-
tive effect of metronidazole compared to penicillin with
a significantly lower mortality rate, a shorter stay in
hospital, and an improved response to treatment,23 but
other reports fail to show significantly superior clinical
responses.22,24 In the current study, a comparison of out-
come between horses treated with metronidazole versus
those treated with penicillin was not possible because of
the few horses that received exclusively metronidazole.
Limitations of this study include its retrospective na-
ture and the large number of reporting clinicians. How-
ever, potential bias was limited by the use of standard-
ized data collection sheets and the high response rate for
most variables in this study. For this study, a large num-
ber of adult horses with tetanus was collected, for a dis-
ease currently considered to be rare in Western Europe.1
The number of foals was limited, and therefore fewer
prognostic factors could be identified. Institution-related
biaswas limited as indicated byperforming the prognos-
tic assessment of Ghent University cases only.
In conclusion, this study demonstrates that the out-
come of equine tetanus patients is still poor in Europe.
Outcome and prognostic factors are similar in foals and
adult horses. The prognostic assessment of cases with
tetanus provides clinicians with new evidence-based in-
formation related to patient management. Several prog-
nostic indicators are related to the ability to eat or drink,
and in general more severe clinical signs are associated
to poorer outcome. Although positive trends were iden-
tified, the study failed to demonstrate a statistically sig-
nificant effect on outcome for increasing intravenously
administered dosages of TAT. Providing more intensive
monitoring andmore intensive and advanced support to
our equine patientsmaybe key to improving the progno-
sis in the future. The strongest emphasis should remain
on prevention through vaccination.
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